The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Growth in CDMO should pick up in the next few quarters given Akums’ healthy order book alongside API prices also settling. EBITDA margins leaped 160bps to 12% as the company curbs losses (down ...

API EBITDA losses reduced significantly in Q3 YoY, although prices of cephalosporin APIs ... With our focus on establishing Akums' global CDMO footprint, we took a significant step by securing ...

New Delhi [India], February 8: Akums Drugs and Pharmaceuticals Ltd., has announced its consolidated financial results for the quarter ended December 31, 2024, delivering 12% increase in Adjusted ...

Akums Drugs and Pharmaceuticals Ltd., has announced its consolidated financial results for the quarter ended December 31, ...

Akums saw a 15% year-over-year rise in adjusted profit after tax (PAT), attributed to a refined product mix and improved profitability within the CDMO scope. Notably, the company achieved a reduction ...

J&K Leather Goods Industry: Vast Potential & Training Opportunities Union minister highlights vast potential of J&K's leather goods industry. Training program launched to empower women ...

Billionaire investor William Ackman increased his stake in sportswear company Nike by 15% and cut his investment in ...